ESMO 2025 | DAREON-8研究首次揭晓，Obrixtamig探索ES-SCLC一线治疗新路径

*仅供医学专业人士阅读参考

*以下内容仅供医疗卫生专业人士浏览。

调研问题

专家简介

艾星浩 教授

上海市胸科医院 肿瘤内科

• 医学博士，上海市胸科医院肺部肿瘤临床医学中心副主任医师，硕士生导师

• 中国医药教育协会肿瘤免疫治疗专业委员会委员
  

• 中国抗癌协会科普委员会委员
  

• 中国抗癌协会免疫治疗专业委员会委员
  

• 中国肺癌防治联盟肺癌免疫治疗委员会委员
  

• 吴阶平医学基金会肿瘤多学科诊疗专业委员会副秘书长
  

• 上海市女医师协会肺癌专业委员会副主任委员
  

• 上海市抗癌协会肿瘤免疫治疗专业委员会秘书长
  

• 上海市康复医学医疗器械专业委员会委员

• JCO

  中文编委

• 2021年获中华医学科学技术奖二等奖
  

• 2023年获上海医学科技奖一等奖

参考文献：

[1]中国临床肿瘤学会小细胞肺癌专家委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 小细胞肺癌免疫治疗专家共识（2025版）. 中华肿瘤杂志. 2025. 47(01): 65-75.

[2]Ogieuhi IJ, Ajekiigbe VO, Oladipo TC, et al. Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer. Clin Transl Oncol. 2025 .

[3]Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years. Oncologist. 2007. 12(9): 1096-104.

[4]Solange Peters, et al. DAREON®-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). 2025 ESMO. 2759MO .

[5]郑荣寿, 陈茹, 韩冰峰等. 2022年中国恶性肿瘤流行情况分析. 中华肿瘤杂志. 2024. 46(03): 221-231.

[6]Wermke M, Gambardella V, Kuboki Y, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025. 43(27): 3021-3031.

[7]Xie J, Chen M, Han H, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023. 14(15): 1327-1338.

[8]Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018. 379(23): 2220-2229.

[9]Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021. 22(1): 51-65.

[10]Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022. 23(6): 739-747.

[11]Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024. 19(7): 1073-1085.

[12]Cheng Y, Zhang W, Wu L, et al. Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial. JAMA Oncol. 2025. 11(1): 16-25.

[13]Martin Wermke, Jürgen Alt, Farastuk Bozorgmehr, et al. DAREON-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. 2025 ASCO Abstract 8094 .

[14]Martin Wermke, Juergen Alt, Farastuk Bozorgmehr, et al. DAREON®-9: A phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients (pts) with advanced small-cell lung cancer (SCLC): Updated results. 2025 ESMO. 2774P .

[15]Marianne E. Pavel, Chris Verslype, Pedro Rocha, et al. Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Trial in progress of the dose expansion part of the phase II DAREON®-5 trial. 2025 ESMO. 1731TiP .

[16]Aman Chauhan, Saori Mishima, Ana Custodio, et al. DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas. 2025 NANETS. -8 .

审批号：SC-CN-18189, 有效期至：11/3/2026

*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。